Showing results (371-380 of 400) with videos related to

Sort By:
Pageof 40
Communications Biology|November 22, 2025
Systematic evaluation of tools used for single-cell m<sup>6</sup>A identificationYueqi Li, Xinyue Xu, Mingcong Chen, et al.
International Journal of Clinical and Experimental Medicine|July 2, 2015
Differential lncRNA expression profiles in recurrent gliomas compared with primary gliomas identified by microarray analysisYi Chen, Jian-Jin Wu, Xian-Bin Lin, et al.
Proceedings of the National Academy of Sciences of the United States of America|June 13, 2018
Hypoxic tumor microenvironment activates GLI2 via HIF-1α and TGF-β2 to promote chemoresistance in colorectal cancerYen-An Tang, Yu-Feng Chen, Yi Bao, et al.
Nature Communications|January 20, 2026
Intermittent fasting inhibits Tp53-driven glioma through gut microbiota-mediated methionine-m<sup>6</sup>A regulationYao Lin, ShihJung Li, Xinyue Xu, et al.
Journal of Integrative Medicine|October 18, 2020
Effects of Tanreqing Capsule on the negative conversion time of nucleic acid in patients with COVID-19: A retrospective cohort studyXing Zhang, Yan Xue, Xuan Chen, et al.
Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine|September 28, 2015
Anti-tumor activity of phenoxybenzamine hydrochloride on malignant glioma cellsXian-Bin Lin, Lei Jiang, Mao-Hua Ding, et al.
Advanced Science (Weinheim, Baden-Wurttemberg, Germany)|July 10, 2022
In-Memory Mathematical Operations with Spin-Orbit Torque DevicesRuofan Li, Min Song, Zhe Guo, et al.
Eclinicalmedicine|January 1, 2026
Efficiency and safety of sintilimab-based induction therapy in potentially resectable stage III non-small cell lung cancer (LungMate-009): an open-label, phase 2 trialTao Ge, Hongyi Zhang, Xinsheng Zhu, et al.
Proceedings of the National Academy of Sciences of the United States of America|November 27, 2023
Targeting the lipid kinase PIKfyve upregulates surface expression of MHC class I to augment cancer immunotherapyYi Bao, Yuanyuan Qiao, Jae Eun Choi, et al.
Nature Communications|October 28, 2015
IRAK1 is a therapeutic target that drives breast cancer metastasis and resistance to paclitaxelZhen Ning Wee, Siti Maryam J M Yatim, Vera K Kohlbauer, et al.
Pageof 40